Novo, Pfizer Boost Metsera Bids in Obesity Startup Battle
PositiveFinancial Markets

Pfizer and Novo Nordisk are intensifying their competition for the obesity startup Metsera, with Novo's latest bid valuing the company at an impressive $10 billion, significantly higher than Pfizer's $8.1 billion offer. This battle highlights the growing interest and investment in obesity treatments, which are becoming increasingly important as obesity rates rise globally. The outcome of this bidding war could shape the future of obesity care and innovation.
— Curated by the World Pulse Now AI Editorial System













